Her2/ERBB2 Protein, Human, Recombinant (ECD)

1/3
Price:
Size:
Number:

Her2/ERBB2 Protein, Human, Recombinant (ECD): Product Information

Purity
> 95 % as determined by SDS-PAGE.
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
Activity
1.Measured by its binding ability in a functional ELISA.
2.Immobilized human ErbB2 (Cat:10004-HCCH) at 10μg/mL (100μL/well) can bind herceptin ,the EC50 of herceptin is 7-90ng/mL.
3.Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.4-2.4μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.
Protein Construction
A DNA sequence encoding the human ERBB2 (NP_004439.2) (Met1-Thr652) was expressed with five amino acids (DDDDK) at the C-terminus.
Accession#
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Thr 23
Molecule Mass
The recombinant human ERBB2 consists 636 amino acids and predicts a molecular mass of 70 kDa. As a result of glycosylation, human ErbB2 migrates as an approximately 100-110 kDa protein in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

Her2/ERBB2 Protein, Human, Recombinant (ECD): Images

Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.4-2.4μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.
Measured by its binding ability in a functional ELISA. Immobilized human ErbB2 (Cat: 10004-HCCH) at 10 μg/mL (100 μL/well) can bind herceptin, the EC50 of herceptin is 7-90 ng/mL.

Her2/ERBB2 Protein, Human, Recombinant (ECD): Synonyms

CD340 Protein, Human; ENV Protein, Human; ENVW Protein, Human; ERVWE1 Protein, Human; HER-2 Protein, Human; HER-2/neu Protein, Human; HER2 Protein, Human; HERV-7q Protein, Human; HERV-W-ENV Protein, Human; HERV7Q Protein, Human; HERVW Protein, Human; HERVWENV Protein, Human; MLN 19 Protein, Human; MLN19 Protein, Human; NEU Protein, Human; NGL Protein, Human; TKR1 Protein, Human

Her2/ERBB2 Background Information

Epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD34, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
Full Name
erb-b2 receptor tyrosine kinase 2
References
  • Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.
  • Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments
    Author
    Egan, TJ;Diem, D;Weldon, R;Neumann, T;Meyer, S;Urech, DM;
    Year
    2016
    Journal
    MAbs
    Application
    SPR
  • Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysates
    Author
    Eletxigerra, U;Martinez-Perdiguero, J;Barderas, R;Pingarrón, JM;Campuzano, S;Merino, S;
    Year
    2016
    Journal
    Anal. Chim. Acta
    Application
    binding
  • Molecular and hydrodynamic properties of human epidermal growth factor receptor HER2 extracellular domain and its homodimer: Experiments and multi-scale simulations
    Author
    Vega, JF;Ramos, J;Cruz, V;Vicente-Alique, E;Sánchez-Sánchez, E;Sánchez-Fernández, A;Wang, Y;Hu, P;Cortés, J;Martínez-Salazar, J;
    Year
    2017
    Journal
    Biochim. Biophys. Acta
    Application
    monitor the transport properties of HER2 in solution
  • para-Sulfonatocalix[4]arene stabilized gold nanoparticles multilayers interfaced to electrodes through host-guest interaction for sensitive ErbB2 detection.
    Author
    Wang, X;Du, D;Dong, H;Song, S;Koh, K;Chen, H;
    Year
    2017
    Journal
    Biosens Bioelectron
    Application
    Fabrication of ErbB2 biosensor and electrochemistry detection
  • ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab
    Author
    Agnolon, V;Contato, A;Meneghello, A;Tagliabue, E;Toffoli, G;Gion, M;Polo, F;Fabricio, ASC;
    Year
    2020
    Journal
    Sci Rep
    Application
    SPR and ELISA (standard); ELISA
  • High-resolution mapping of glycoprotein structure–activity relationships by shotgun scanning glycomutagenesis
    Author
    Li, M;Zheng, X;Shanker, S;Jaroentomeechai, T;Koçer, I;Byrne, J;Cox, E;Labonte, J;Gray, J;DeLisa, M;
    Year
    2020
    Journal
    bioRxiv
    Application
    Elisa
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.